格雷夫斯眼病的评估与治疗。
The evaluation and treatment of graves ophthalmopathy.
机构信息
Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
出版信息
Med Clin North Am. 2012 Mar;96(2):311-28. doi: 10.1016/j.mcna.2012.01.014. Epub 2012 Feb 22.
Abstract
Optimum care of the patient with Graves ophthalmopathy (GO) is achieved through teamwork between the endocrinologist and ophthalmologist, with input from ancillary specialists as needed. Clinical evaluation should include determination of both the severity and the activity of the disease. It is important to assess early in the evaluation the impact of the disease on the patient's quality of life and their priorities and expectations regarding management. Once this information has been gathered, careful discussion between patient and physicians can define the management plan. This article reviews the pathophysiology, epidemiology, evaluation, and management of GO.
摘要
Graves 眼病（GO）患者的最佳治疗需要内分泌医生和眼科医生的团队合作，并根据需要由辅助专家提供意见。临床评估应包括确定疾病的严重程度和活动度。在评估早期评估疾病对患者生活质量的影响以及他们对管理的优先事项和期望非常重要。一旦收集到这些信息，患者和医生之间的仔细讨论可以确定管理计划。本文综述了 GO 的发病机制、流行病学、评估和管理。
相似文献
1
The evaluation and treatment of graves ophthalmopathy.格雷夫斯眼病的评估与治疗。
Med Clin North Am. 2012 Mar;96(2):311-28. doi: 10.1016/j.mcna.2012.01.014. Epub 2012 Feb 22.
2
Practical Guidelines Management of Graves Ophthalmopathy.格雷夫斯眼病的实用管理指南
Acta Med Indones. 2019 Oct;51(4):364-371.
3
[Graves' Orbitopathy].[格雷夫斯眼眶病]
Klin Monbl Augenheilkd. 2016 Dec;233(12):1385-1407. doi: 10.1055/s-0042-118040. Epub 2016 Nov 21.
4
[Drug therapy and radiotherapy in Graves' orbitopathy].[格雷夫斯眼眶病的药物治疗与放射治疗]
Ophthalmologe. 2011 May;108(5):425-31. doi: 10.1007/s00347-010-2187-7.
5
Viral conjunctivitis interfering with the clinical activity score and management of thyroid ophthalmopathy.病毒性结膜炎干扰甲状腺眼病的临床活动评分及治疗。
Orbit. 2006 Mar;25(1):27-9. doi: 10.1080/01676830500505871.
6
[Update on endocrine orbitopathy].[内分泌性眼眶病的最新进展]
Klin Monbl Augenheilkd. 2009 Feb;226(2):R13-28; quiz R29-31. doi: 10.1055/s-2008-1038911. Epub 2009 Feb 10.
7
[Current management of endocrine orbitopathy].[内分泌性眼眶病的当前管理]
Med Klin (Munich). 2008 Oct 15;103(10):717-30; quiz 729-30. doi: 10.1007/s00063-008-1112-1.
8
Optimal management of Graves orbitopathy: a multidisciplinary approach.格雷夫斯眼眶病的优化管理：多学科方法
Neth J Med. 2011 Jul-Aug;69(7):302-8.
9
[Ocular myopathies and autoimmunity].[眼肌病与自身免疫]
Klin Monbl Augenheilkd. 2014 Sep;231(9):e47, e49-65; quiz e66-7. doi: 10.1055/s-0033-1357975. Epub 2014 Aug 12.
10
[Graves' ophthalmopathy].[格雷夫斯眼病]
Ophthalmologe. 2016 Apr;113(4):349-64; quiz 465-6. doi: 10.1007/s00347-016-0239-3.
引用本文的文献
1
Correlation Between Changes in Extraocular Muscles and Intraocular Pressure Following Anti-Inflammatory Therapy in Active Thyroid Eye Disease.活动性甲状腺眼病抗炎治疗后眼外肌变化与眼压之间的相关性
J Clin Med. 2025 Feb 23;14(5):1480. doi: 10.3390/jcm14051480.
2
Monocyte to high-density lipoprotein cholesterol ratio as a predictor of the activity of thyroid-associated ophthalmopathy.单核细胞与高密度脂蛋白胆固醇比值作为甲状腺相关性眼病活动度的预测指标。
Int J Ophthalmol. 2024 Dec 18;17(12):2276-2281. doi: 10.18240/ijo.2024.12.16. eCollection 2024.
3
Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study.托珠单抗治疗中重度糖皮质激素抵抗性甲状腺眼病患者的疗效：一项前瞻性研究。
Int Ophthalmol. 2024 Apr 16;44(1):179. doi: 10.1007/s10792-024-03117-6.
4
The Relationship between Obesity-Related Factors and Graves' Orbitopathy: A Pilot Study.肥胖相关因素与格雷夫斯眼病的关系：一项初步研究。
Medicina (Kaunas). 2022 Nov 29;58(12):1748. doi: 10.3390/medicina58121748.
5
The promising role of risk scoring system for Cushing syndrome: Time to reconsider current screening recommendations.风险评分系统在库欣综合征中的应用前景：是时候重新考虑当前的筛查建议了。
Front Endocrinol (Lausanne). 2022 Nov 22;13:1075785. doi: 10.3389/fendo.2022.1075785. eCollection 2022.
6
A Systematic Review on the Role of Antioxidants in Thyroid Eye Disease.抗氧化剂在甲状腺眼病中作用的系统评价
J Curr Ophthalmol. 2022 Apr 16;34(1):16-24. doi: 10.4103/joco.joco_266_21. eCollection 2022 Jan-Mar.
7
Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves' Orbitopathy.不同静脉注射糖皮质激素方案治疗Graves眼病的网状Meta分析
Front Pharmacol. 2022 Apr 26;13:785757. doi: 10.3389/fphar.2022.785757. eCollection 2022.
8
Mycophenolate Mofetil (CellCept®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy.霉酚酸酯（骁悉®）联合低剂量泼尼松龙治疗中重度格雷夫斯眼眶病
Front Med (Lausanne). 2022 Feb 11;9:788228. doi: 10.3389/fmed.2022.788228. eCollection 2022.
9
An Interesting Case of Euthyroid Graves' Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies.一例促甲状腺激素受体抗体阴性的甲状腺功能正常的Graves眼病的有趣病例。
Cureus. 2021 Oct 24;13(10):e19015. doi: 10.7759/cureus.19015. eCollection 2021 Oct.
10
A systematic review of euthyroid Graves' disease (Review).正常甲状腺功能的格雷夫斯病的系统评价（综述）
Exp Ther Med. 2021 Nov;22(5):1346. doi: 10.3892/etm.2021.10781. Epub 2021 Sep 22.
本文引用的文献
1
High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now?高剂量静脉注射糖皮质激素治疗格雷夫斯眼病：我们目前处于什么阶段？
Thyroid. 2012 Jan;22(1):1-2. doi: 10.1089/thy.2012.2201.ed.
2
Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.格雷夫斯眼病糖皮质激素治疗的致死性和非致死性不良事件：一项在欧洲甲状腺协会成员中开展的问卷调查。
Eur J Endocrinol. 2012 Feb;166(2):247-53. doi: 10.1530/EJE-11-0779. Epub 2011 Nov 4.
3
Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.甲状腺功能亢进症和其他原因引起的甲状腺毒症：美国甲状腺协会和美国临床内分泌医师协会的管理指南。
Endocr Pract. 2011 May-Jun;17(3):456-520. doi: 10.4158/ep.17.3.456.
4
Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?格雷夫斯眼病中的自身免疫：促甲状腺激素受体和 IGF-1 受体之间不幸联姻的结果？
J Clin Endocrinol Metab. 2011 Aug;96(8):2386-94. doi: 10.1210/jc.2011-0307. Epub 2011 Jun 15.
5
Selenium and the course of mild Graves' orbitopathy.硒与轻度格雷夫斯眼病的病程。
N Engl J Med. 2011 May 19;364(20):1920-31. doi: 10.1056/NEJMoa1012985.
6
Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.甲状腺功能亢进症及其他原因所致甲状腺毒症：美国甲状腺协会和美国临床内分泌医师学会管理指南。
Thyroid. 2011 Jun;21(6):593-646. doi: 10.1089/thy.2010.0417. Epub 2011 Apr 21.
7
A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.促甲状腺激素受体抗体通过激活 Graves 眼病眼眶前体细胞中的磷酯酰肌醇 3-激酶促进脂肪生成。
J Mol Endocrinol. 2011 Apr 12;46(3):155-63. doi: 10.1530/JME-11-0006. Print 2011 Jun.
8
Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.临床综述：静脉内给予糖皮质激素治疗格雷夫斯眼病：疗效和发病率。
J Clin Endocrinol Metab. 2011 Feb;96(2):320-32. doi: 10.1210/jc.2010-1962. Epub 2011 Jan 14.
9
10
Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.促甲状腺素受体刺激性 Graves 眼病免疫球蛋白不仅通过环腺苷酸信号通路诱导 Graves 眼病患者分化的眼眶成纤维细胞合成透明质酸。
Thyroid. 2011 Feb;21(2):169-76. doi: 10.1089/thy.2010.0123. Epub 2010 Oct 18.
Zotero 插件